Trial Profile
A Randomized, Open-Label, Controlled, Multi-Center Phase II Study to Evaluate the Efficacy and Safety of Adecatumumab Alone or Sequentially to FOLFOX Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Oct 2021
Price :
$35
*
At a glance
- Drugs Adecatumumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Cancer metastases; Colorectal cancer
- Focus Therapeutic Use
- Sponsors Amgen
- 10 Nov 2011 Actual patient number is 35 according to ClinicalTrials.gov.
- 10 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Nov 2011 Actual end date (November 2011) added as reported by ClinicalTrials.gov.